

Safety of administering biologics to IBD patients at an outpatient infusion center In New York City during the COVID-19 pandemic: Sars-CoV-2 seroprevalence and clinical and social characteristics

Keywords: inflammatory bowel disease, Crohn's disease, ulcerative colitis, coronavirus disease 2019, infusion center, seroprevalence, biologics

Authors:

Serre-Yu Wong, MD, PhD, The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Stephanie Gold, MD, The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Emma K. Accorsi, BS, Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA

Tori L. Cowger, MPH, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA

Dean Wiseman, BS, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Reema Navalurkar, BS, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Rebekah Dixon, BS, The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Drew S. Helmus, MPH, The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

CiTI Study Group[#]

Adolfo Firpo-Betancourt, MD, Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Damodara Rao Mendu, PhD, Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Susan Zolla-Pazner, PhD, Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Ken Cadwell^{*}, PhD, Department of Microbiology, Division of Gastroenterology and Hepatology, Department of Medicine, New York University School of Medicine, New York, New York, USA

Jean-Frederic Colombel^{*}, MD, The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

^{*}These authors contributed equally.

[#]CiTI Study Group: Jessica Anne Neil, Stela Sota, Kyung Ku Jang, Krystal Ching, Mericien Venzon, Xiaomin Yao, Lucie Bernard, Vicky Martinez, Xin Chen, Vincenza R. Itri, Michelle Mendiolaza, Pamela Reyes-Mercedes, Sara Nunez, Stephanie Stanley,

Darwin Jimenez, Alexa Riggs, Michael Tankelevich, Brianne Phillipe, Julio Ramos, Liangyuan Hu, Jiayi Ji, Sheila D. Rustgi, and Lauren Tal Grinspan

Correspondence: Serre-Yu Wong, MD, PhD, One Gustave L. Levy Place, Box 1069, New York, New York 10029, USA, Serre-Yu.Wong@mountsinai.org, Telephone: 212-241-3179

Supported by: This work was supported by the Hemlsey Trust, Cure for IBD, T32AI007535 from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The Mount Sinai Serological Sciences Network (SeroNet) is supported by Federal funds from the National Cancer Institute, National Institutes of Health, under contract no. 5N91019D00024, task order no. 75N91020F00003 and under U54 CA260560-01. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.

Author Contributions: SYW contributed to the study concept and design, analysis and interpretation of data, drafting of manuscript, and critical revision of the manuscript for important intellectual content. SG contributed to the acquisition and analysis of the data.

EKA and TLC contributed to the study concept and design, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content. DW contributed to analysis of the data. RD and DSH contributed to the acquisition of the data and critical revision of the manuscript for important intellectual content. RN, AFB, and DRM contributed to the acquisition of data. The CiTI Study Group contributed to acquisition and analysis of data. SZP contributed to the study concept and design, analysis of data, and critical revision of the manuscript for important intellectual content. KC and JFC contributed to the study concept and design, interpretation of data, drafting of manuscript, and critical revision of the manuscript for important intellectual content

Conflicts of interest: Ken Cadwell reported receiving research funding from Pfizer, Takeda, and Abbvie; has consulted for or received an honorarium from Puretech Health, Genentech, and Abbvie; and holds U.S. patent 10,722,600 and provisional patent 62/935,035. Jean-Frederic Colombel reported receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire, Takeda and Tillots; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, Imtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, Viela bio; and holding stock options in Intestinal Biotech Development. Mount Sinai has licensed serological assays to commercial entities and has filed for

patent protection for serological assays (US provisional application no. 63/059,924). Mount Sinai has also founded a subsidiary, Kantaro Biosciences, to market a commercial version of the assay described in this manuscript. The remaining authors disclose no conflicts.

Abstract

Patients with immune-mediated inflammatory diseases (IMIDs) and acquired and genetic immunodeficiencies receiving therapeutic infusions are considered high risk for SARS-CoV-2 infection. However, the seroprevalance in this group and the safety of routine administrations at outpatient infusion centers are unknown. To determine the infection rate and clinical-social factors related to SARS-CoV-2 in asymptomatic patients with IMIDs and immunodeficiencies receiving routine non-cancer therapeutic infusions, we conducted a seroprevalence study at our outpatient infusion center. We report the first prospective SARS-CoV-2 sero-surveillance of 444 IBD/IMID, immunodeficiency, and immune competent patients at an outpatient infusion center in the U.S. showing lower seroprevalence in patients compared with the general population and provide clinical and social characteristics associated with seroprevalence in this group. These data suggest that patients can safely continue infusions at outpatient centers.

Introduction

Due to their underlying conditions and frequent treatment with infusion medications that modulate the immune system, patients with inflammatory bowel disease (IBD) are considered high-risk for COVID-19. Since the beginning of the COVID-19 pandemic, clinical guidelines have advised patients to maximize shielding, and many patients receiving infusion therapies switched from infusion centers to home infusions or chose to delay or discontinue treatments.^{1,2} This places them at risk for treatment discontinuation, increased home exposures in the case of home infusions, and poor

outcomes because of stopping therapies.^{2,3} However, the risk of SARS-CoV-2 infection in IBD patients receiving their care in an outpatient infusion center is unknown.

We thus screened patients for SARS-CoV-2 antibodies at our high-volume therapeutic infusion center in New York City during the height of the COVID-19 pandemic, including during lockdown when access to patients was limited, and assessed the contributions of social and clinical factors to seroprevalence. We reasoned that these patients might take greater shielding precautions due to COVID-19, which could contribute to seroprevalence, so we collected data on social exposures by a questionnaire.

Methods

This was a cross-sectional study conducted from May 26 to July 15, 2020, at the Mount Sinai Therapeutic Infusion Center. We recruited adult patients aged 18 years and older (range 18-93) with scheduled appointments. All patients were negative for COVID-19 symptoms at the time of blood collection. For a general population control, we utilized previously-published SARS-CoV-2 serological testing data of 2,123 routine care patients at the same institution during the same time period.⁴

Patient data including sex, infusion diagnoses, infusion medications, and lab values (hemoglobin, platelets, albumin, CRP, and ESR) were obtained from medical records. Participants were asked to complete questionnaires to report demographics, residential zip codes, medical history, COVID-19 symptom and testing history, and social exposures. Sera was tested using the (1) Emergency Use Authorization (EUA) Mount

Sinai Health System Kantaro SeroKlir assay to compare results with data from the general population control, and (2) EUA Siemens Healthineers SARS-CoV-2 Total (COV2T) assay (Supplemental Methods).^{4,5} The Icahn School of Medicine at Mount Sinai Institutional Review Board approved the study. Statistical analysis was performed using R v3.5.3 (Supplemental Methods).

Results

Overall 444 patients were recruited at the infusion center. The Kantaro SeroKlir results showed a 13.5% (52/383) SARS-CoV-2 seroprevalence in infusion center patients which was lower than 18.5% (393/2123) reported in a the general control population ($p = 0.02$).⁴

The Siemens COV2T assay, which has shown the highest sensitivity and specificity in comparative analyses, was used for all further analyses to broaden applicability of the data.⁵ Overall seroprevalence was 9% (40/444). Details of patient demographics, diagnostics and therapies are in Table 1. The seroprevalence was 9.4% (35/373) in IMID patients, including 9% in IBD (21/235), 22% (4/18) in immunocompetent patients, and 1.9% (1/53) in patients with acquired or genetic immunodeficiencies. Of IBD patients, seroprevalence was 7.8% in Crohn's disease (11/141) and 10.6% in ulcerative colitis and IBD-unclassified (10/94) patients. Seropositive patients displayed the expected range of antibody titres (Figure 1).

The proportion of seropositive males (14%, 25/178) was higher than that of females (5.6%, 15/266). There were significant differences in seroprevalence by race and ethnicity, with the lowest seroprevalence in non-Hispanic white patients (5.6%, 11/197) compared with other groups. There were no significant associations with age, smoking status, or comorbid conditions previously established to be COVID-19 risk factors.

Among 288 of 444 patients who completed the questionnaire, SARS-CoV-2 seroprevalence was associated with COVID-19 symptoms and household member(s) testing positive for SARS-CoV-2 infection (PR: 8.37 [4.23,16.56], $p < 10^{-5}$), speaking a language other than English at home (PR: 2.63 [1.23, 5.61], $p = 0.019$), household crowding (PR: 4.31 [2.06, 9.04], $p < 10^{-3}$), primary residence type ($p = 0.010$), and use of public transportation (PR: 3.26 [1.51,7.04], $p = 0.003$). Of note, 25 of the 40 seropositive patients completed questionnaires, of whom 6 answered that they had no symptoms from January 2020 until the time of their blood draw, indicating asymptomatic seroconversion. Seroprevalence by reported home zip codes for 183 participants living in NYC was mapped (Figure 1). Mask wearing was 100% (43/43) among patients who reported non-remote employment and 98.5% (85/86) among those who utilized public transportation.

Discussion

Our findings indicate that the SARS-CoV-2 seroprevalence of IBD patients receiving routine treatments at an outpatient infusion center is lower than that of a general population control. There was a high rate of mask wearing in this cohort, suggesting that

shielding could have been protective. The analyses reveal that social, demographic, and geographic factors for SARS-CoV-2 infection that are well-characterized in the general population extend to IBD patients. To our knowledge, this is the first prospectively-collected seroprevalence data from a single large-volume non-oncologic outpatient infusion center at the height of the COVID-19 pandemic in New York City.

A study of German IMiD patients receiving anti-cytokine therapies also showed a lower seroprevalence compared with control populations.⁶ Studies of IBD patients in Italy and Germany and the United Kingdom receiving infusion medications infliximab and vedolizumab showed that seroprevalence was not higher in IBD patients than controls.⁷⁻⁹ However, the general population seroprevalence in those regions were low.

Several important points can be made from the social questionnaire data. First, there was a high rate of mask wearing in this cohort, suggesting that shielding could have been protective. Second, these data substantiate the evidence for close, household contact as a primary risk factor for SARS-CoV-2 infection. Third, we confirm that well-characterized inequities by race/ethnicity and socioeconomic status extend to this cohort, and demonstrate that conditions related to work, housing, and transportation were also associated with increased prevalence of infection.¹⁰ These social and environmental conditions are shaped by structural racism and economic inequity and may explain observed inequities in COVID-19 burden. Fourth, analysis of zip codes shows higher seropositivity of patients living in areas of the New York City metropolitan

area known to have higher rates of COVID-19 positivity, indicating seroprevalence in infusion center patients reflects the seroprevalence where they reside.

Strengths of this study include prospective data collection, first reporting of IBD receiving infusions at a large-volume outpatient center in the U.S., comparison of IBD patients to a general population control, other IMIDs, and immunodeficient patients, and comprehensive clinical and social exposure analysis. A limitation of the study is that it is from a single center.

In conclusion, our data suggest patients can safely continue routine infusions at outpatient centers during the COVID-19 pandemic as the seroprevalence at our center was low; longitudinal follow-up of these patients would confirm this point. This information is useful to practitioners as many patients have opted to delay or discontinue infusions during the pandemic, risking disease flares and complications thereof, or switched to home infusions, which has been associated with adverse outcomes.^{2,3} This is all the more important in our urban cohort given the disparity of seroprevalence by socio-economic factors. Finally, the functionality and durability of immune responses to SARS-CoV-2 infection, as well as COVID-19 vaccines, remain to be determined in IBD patients, who were not included in COVID-19 vaccine trials.

Acknowledgments

The authors wish to thank the patients who participated in the study; the Mount Sinai Therapeutic Infusion Center staff for their contributions to patient recruitment; Siemens Healthineers and the Icahn School of Medicine at Mount Sinai Seronet Team for their support for serology testing; Gustavo Martinez-Delgado for laboratory support; and Rohit Chandwani, Manasi Agrawal, Viviana Simon, Ania Wajnberg, Saurabh Mehandru, Jack Satsangi, and Charlotte Cunningham-Rundles for thoughtful comments and discussions on study design and data analysis and presentation.

Table 1: Selected Demographic Characteristics by SARS-CoV-2 Antibody Presence

Characteristic	Overall N, N = 444	SARS-COV2 Antibody Negative N=404	SARS-COV2 Antibody Positive N=40	P-value		
Age, years, mean (SD)	444	44.2 (16.9)	46.40 (17.4)	0.46		
Sex	Male	178	153 (86%)	25 (14%)	0.004	
	Female	266	251 (94.4%)	15 (5.6%)		
Race/Ethnicity ^a	Non-Hispanic Asian	13	11 (84.6%)	2 (15.4%)	0.016	
	Hispanic/Latin	44	37 (84.1%)	7 (15.9%)		
	More than one race	3	3 (100%)	0 (0%)		
	Non-Hispanic Black	24	21 (87.5%)	3 (12.5%)		
	Non-Hispanic Native Hawaiian or other Pacific Islander	1	0 (0%)	1 (100%)		
Smoking Status ^a	Non-Hispanic white	197	186 (94.4%)	11 (5.6%)	0.92	
	Never smoker	218	198 (90.8%)	20 (9.2%)		
	Former smoker	58	53 (91.4%)	5 (8.6%)		
	Current smoker	10	10 (100%)	0 (0%)		
Comorbidities	Any Comorbidity	178	157 (88.2%)	21 (11.8%)	0.13	
	Asthma/Chronic obstructive pulmonary disease	47	41(87.2%)	6(12.8%)	0.41	
	Obesity	104	92(88.4%)	12(11.6%)	0.23	
	Hypertension	70	65 (92.8%)	5 (7.2%)	0.65	
	Coronary artery disease	11	9(81.8%)	2 (18.2%)	0.26	
	Chronic kidney disease	20	19(95%)	1(5%)	>0.99	
	Diabetes	22	20(91%)	2(9%)	>0.99	
Infusion Diagnosis ^c	Immune competent	18	14 (77.8%)	4 (22.2%)	0.021	
	All IMID	373	338 (90.6%)	35 (9.4%)		
	Immunodeficiency state ^b	53	52 (98.1%)	1 (1.9%)		
	Detailed infusion diagnosis					
	IBD	235	214 (91%)	21 (9%)		>0.99
	MS/NMO	64	59 (92.2%)	5 (7.8%)		0.82
	Other IMID	53	48 (90.6%)	5 (9.4%)		>0.99
	Primary immunodeficiency	33	32 (97%)	1 (3%)		0.34
	Asthma/Urticaria	21	17 (81%)	4 (19%)		0.11
	Solid organ transplant	19	19 (100%)	0 (0%)		0.40
Infusion Medication ^d	Immune competent	18	14 (77.8%)	4 (22.2%)	0.046	
	HIV	1	1(100%)	0(0%)	>0.99	
	Anti-TNF	143	131 (91.6%)	12 (8.4%)	0.86	
	Anti-alpha-4 beta-7 integrin	81	73 (90.2)	8 (9.8%)	0.83	
	Anti alpha-4 integrin	31	26 (84%)	5 (16%)	0.18	
	IVIg	40	38 (95%)	2 (5%)	0.56	
	Anti-BAFF	10	8 (80%)	2 (20%)	0.22	
	Anti-CD20	40	40 (100%)	0 (0%)	0.038	
	CTLA-4-IG fusion proteins	22	21 (94.4%)	1 (5.6%)	0.71	
	Anti-IL12/23	25	23 (92%)	2 (8%)	>0.99	
	Anti-IL23	2	2 (100%)	0(0%)	>0.99	
	Anti-IL6R	3	3 (100%)	0(0%)	>0.99	
	Anti-IgE	14	11 (78.6%)	3 (21.4%)	0.12	
	Anti-IL-5/IL-5R	7	6 (85.8%)	1 (14.2%)	0.49	
	Laboratory Data ^e	Solumedrol	2	2 (100%)	0(0%)	>0.99
C1 Esterase Inhibitor		1	1 (100%)	0(0%)	>0.99	
Other		23	19 (82.6%)	4 (17.4%)	0.14	
Hg, mean (SD)		381	12.0 (1.54)	12.68 (1.54)	0.38	
Plt, mean (SD)		379	269.4 (85.8)	248.3 (85.5)	0.19	
CRP, mean (SD)		232	6.14 (9.93)	9.9 (13.1)	0.22	
ESR, mean (SD)		245	19.61 (20.6)	18.17 (21.4)	0.76	

	Alb, mean (SD)	350	4.001(0.41)	4.065 (0.41)	0.42
Questionnaire Completion	Incomplete	156	141 (90.4%)	15 (9.6%)	0.88
	Complete	288	263 (91.3%)	25 (8.7%)	
Language other than English spoken at home ^a	No	208	196 (94.2%)	12 (5.8%)	0.019
	Yes	79	67 (84.8%)	12 (15.2%)	
Flu vaccine Fall/Winter 2019? ^a	Yes	143	128 (89.5%)	15 (10.5%)	0.40
	No	143	133 (93%)	10 (7%)	
Reported COVID-19 related symptoms since January 2020 ^a	No reported symptoms	86	79 (91.8%)	7 (8.2%)	0.82
	1+ symptoms	182	165 (90.6%)	17 (9.4%)	
	Fever	60	48 (80%)	12 (20%)	0.003
	Cough	79	66 (83.6%)	13 (16.4%)	0.001
	Shortness of breath	42	32 (76.2%)	10 (23.8%)	<0.001
	Chest tightness	30	23 (76.6%)	7 (23.4%)	0.004
	Tiredness/fatigue	109	95(87.2%)	14 (12.8%)	0.070
	Muscle or joint pain	82	70 (85.4%)	12 (14.6%)	0.063
	Nasal congestion	91	81 (89%)	10 (11%)	0.23
	Runny nose	73	63 (86.4%)	10 (13.6%)	0.039
	Sore throat	63	58 (92%)	5 (8%)	0.77
	Headache	81	71 (87.6%)	10 (12.4%)	0.14
	Chills	54	42 (77.8%)	12 (22.2%)	<0.001
	Red/itchy eyes	38	36 (94.8%)	2 (5.2%)	>0.99
	Diarrhea	77	68 (88.4%)	9 (11.6%)	0.20
Vomiting	22	21 (95.4%)	1 (4.6%)	>0.99	
Lack of smell or taste	21	10 (47.6%)	11 (52.4%)	<0.001	
Any household member with positive COVID-19 test ^a	No	265	250 (94.3%)	15 (5.7%)	<0.001
	Yes	19	10 (52.6%)	9 (47.4%)	
Primary Residence Type ^a	Apartment	163	143 (87.7%)	20 (12.3%)	0.01
	Duplex	30	28 (93.3%)	2 (6.7%)	
	House	89	87 (97.8%)	2 (2.2%)	
	Other	3	2 (66.7%)	1 (33.3%)	
Household crowding (more than one person per room) ^a	No	220	208 (94.5%)	12 (5.5%)	<0.001
	Yes	51	39 (76.5%)	12 (23.5%)	
Bus or subway transportation in the past three weeks ^a	Never	200	190 (95%)	10 (5%)	0.003
	1-2 days per week or more	86	72 (83.7%)	14 (16.3%)	
Reported mask wearing on public transportation in the past three weeks ^f	Never	0	0 (0%)	0 (0%)	>0.99
	Rarely	0	0 (0%)	0 (0%)	
	Sometimes	0	0 (0%)	0 (0%)	
	Most of the time	1	1 (100%)	0 (0%)	
	Always	85	71 (83.5%)	14 (16.5%)	
Employment status since March ^a	Unemployed	126	120 (95.2%)	6 (4.8%)	0.031
	Remote	100	92 (92%)	8 (8%)	
	Non-remote	35	31 (88.6%)	4 (11.4%)	
	Multiple statuses	16	12 (75%)	4 (25%)	
	Retired	4	3 (75%)	1 (25%)	
Percent remote work since March ^{a,g}	0%	22	19 (86.4%)	3 (13.6%)	0.29
	1%-50%	16	16 (100%)	0 (0%)	
	51%-99%	37	31 (83.8%)	6 (16.2%)	
	100%	73	67 (91.8%)	6 (8.2%)	
Frequency of PPE use at work ^{a,h}	Never	1	1 (100%)	0 (0%)	0.054
	Rarely	0	0 (0%)	0 (0%)	
	Sometimes	4	4 (100%)	0 (0%)	
	Most of the time	8	4 (50%)	4 (50%)	
	Always	30	27 (90%)	3 (10%)	

a. Variables calculated among the 288 subjects who completed the questionnaire.

- b. Immunodeficiency state – Primary immunodeficiency, HIV, Solid organ transplant
- c. Infusion Diagnoses. IBD: Crohn’s disease, ulcerative Colitis, indeterminate colitis. MS/NMO: Multiple Sclerosis, Neuromyelitis Optica. Primary immunodeficiency: hypogammaglobulinemia, common variable immune deficiency (CVID), hyper-IgM syndrome, X-linked agammaglobulinemia (XLA). Asthma/urticaria: Asthma, Urticaria. Other IMID: Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, psoriasis, hereditary transthyretin-mediated (hATTR) amyloidosis polyneuropathy, systemic lupus erythematosus, rheumatoid arthritis, hereditary angioedema, sarcoid, pemphigus, psoriasis, gout, myasthenia gravis, erosive arthritis, amyopathic dermatomyositis with ILD, hidradenitis suppurativa, ILD/RA, juvenile idiopathic arthritis, neuroendocrine tumor, pachymenitis, spondyloarthropathy. Immune competent: osteoporosis, iron deficiency, dehydration, carcinoid/neuroendocrine tumor, chronic migraine. HIV: Human immunodeficiency virus.
- d. Anti-TNF: infliximab (Remicade, Renflexis), certolizumab (Cimzia). Anti alpha-4 beta-7 integrin: vedolizumab (Entyvio). Anti-alpha-4 integrin: natalizumab (Tysabri). IVIG: Gammagard, Gamunex. Anti-BAFF: belimumab (Benlysta). Anti-CD20: ocrelizumab (Ocrevus), rituximab (Rituxan). Cytotoxic T-lymphocyte antigen-4 (CTLA-4)-IG fusion proteins: belatacept (Nulojix), abatacept (Orencia). Anti-interleukin (IL)-12/23: ustekinumab IV/subcutaneous (Stelara). Anti IL23: Guselkumab (Tremfya), risankizumab (Skyrizi). Anti-IL-6 receptor (anti-IL-6R): tocilizumab (Actemra). Anti-immunoglobulin (Ig) E: omalizumab (Xolair). Anti-IL-5/IL-5R: mepolizumab (Nucala), reslizumab (Cinqair), Fasenna (Benralizumab). Steroid: Solumedrol. Complement C1 esterase inhibitor (Berinert). Other: iron (Injectafer, Venofer, FeraHeme, Ferrlecit), patisiran (Onpattro), normal saline (0.9% NaCl), lanreotide (Somatuline), pegloticase (Krystexxa), zoledronic acid (Reclast), denosumab (Prolia), octreotide (Sandostatin), magnesium, Trogarzo (ibalizumab).
- e. Laboratory values within one month of the infusion date were obtained from medical records.
- f. Data subset to the 86 subjects who reported typically taking the bus or subway 1-2 days per week or more in the past three weeks.
- g. Data subset to the 150 subjects who reported any remote or nonremote employment.
- h. Data subset to the 46 subjects who reported any nonremote employment.


References

1. Rubin DT, et al. *Gastroenterology*. 2020; **159**: 350-357.
2. Horigan JM, et al. *Inflamm Bowel Dis*. 2020; **26**:e137.
3. Fenster M, et al. *Clin Gastroenterol Hepatol*. 2020; **18**: 257-258.
4. Stadlbauer D, Tan J, Jiang K, et al. *Nature*. 2020.
5. National SARS-CoV-2 Serology Assay Evaluation Group. *Lancet Infect Dis*. 2020; **20**: 1390-1400.
6. Simon D, et al. *Nat Commun*. 2020; **11**: 3774.
7. Norsa L, et al. *Gastroenterology*. 2020; **159**: 2229-2231.
8. Berte' R, et al. *J Crohns Colitis*. 2020.
9. McGregor CGC, et al. medRxiv 2020.12.12.20247841.
10. Jay J, et al. *Nat Hum Behav*. 2020; **4**:1294-1302.

Figure 1. Seroprevalence of patients at the Mount Sinai Therapeutic Infusion Center.

(A) Seroprevalence by diagnosis group. (B) Semi-quantitative IgG results for seropositive patients. (C) Seroprevalence by zip code of participants living in NYC.


Figure 1.



C

Participants and Serology Results by Residential Zip Code

NYC participants, n=183*



* n =105 participants not shown. NJ: n=33; NY - Outside NYC: n=49; Other State: n=10; Missing Zip Code: n=13;